华森制药(002907) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥187,539,020.46, a decrease of 7.61% compared to ¥202,986,418.16 in the same period last year[5] - Net profit attributable to shareholders was ¥30,100,541.89, representing a 2.55% increase from ¥29,350,796.60 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 187.54 million, a decrease of 7.15% compared to CNY 202.99 million in Q1 2022[23] - Net profit for Q1 2023 was CNY 30.10 million, representing an increase of 2.55% from CNY 29.35 million in Q1 2022[24] - Basic earnings per share for Q1 2023 were CNY 0.0721, slightly down from CNY 0.0732 in Q1 2022[25] Cash Flow - The net cash flow from operating activities surged by 177.84% to ¥99,370,005.77, compared to ¥35,765,741.17 in the previous year[5][6] - Total cash inflow from operating activities reached ¥290,551,022.84, compared to ¥172,040,485.28 in the previous period, indicating a growth of about 68.8%[26] - The cash outflow from operating activities was ¥191,181,017.07, up from ¥136,274,744.11, which is an increase of approximately 40.4%[26] - The cash inflow from other operating activities was ¥106,755,418.96, a substantial increase from ¥2,969,665.98 in the previous period, representing a growth of about 3,487.5%[26] - The cash and cash equivalents at the end of the period amounted to ¥547,122,756.10, an increase from ¥472,530,734.89 in the previous period, reflecting a growth of approximately 15.7%[27] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,937,718,719.54, up 3.81% from ¥1,866,666,731.37 at the end of the previous year[5] - Total liabilities amounted to CNY 299.96 million, up from CNY 256.28 million in the previous year[21] - The equity attributable to shareholders of the parent company was CNY 1.64 billion, an increase from CNY 1.61 billion year-over-year[21] - The total current assets at the end of the reporting period amounted to 1,015,549,219.51, up from 956,949,388.36 at the beginning of the year[19] Expenses - Research and development expenses increased by 58.41% to ¥14,151,767.59, reflecting the company's commitment to innovation[12] - Total operating costs decreased to CNY 151.82 million, down 9.30% from CNY 167.38 million in the previous year[23] - The company reported a decrease in sales expenses to CNY 52.93 million, down from CNY 54.35 million in the previous year[23] - Tax expenses paid surged to 33,294,627.67, marking a 136.31% increase mainly due to higher value-added tax and additional charges[13] Investment Activities - The net cash flow from investing activities was -¥27,858,952.44, a decline from ¥6,881,474.87 in the previous period, indicating a decrease of 505.5%[27] - The company reported a 100% decrease in cash received from investment recoveries, totaling zero, as there were no financial product redemptions during the period[13] - The cash received from investment income dropped by 80.93% to 163,078.61, primarily due to the absence of financial product redemptions[13] - The company reported a total cash outflow for investing activities of ¥28,022,031.05, down from ¥43,973,675.81 in the previous period, indicating a decrease of approximately 36.2%[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,118, with significant holdings concentrated among the top shareholders[15] Strategic Initiatives - The company plans to gradually offset the negative impact on revenue from the chemical drug segment with new product launches and participation in national procurement[5]